Still, after redefining CYP2C19 *1/*17 patients as CYP2C19 UM patients (n = 302; 32.5%) and reanalysing the association of CYP2C19 metabolizer status with switching/discontinuing AD treatment over time, no significant associations were found (data available from the first author upon request). This evidence concerns the gene CYP2C19 and Alzheimer disease.